Laser treatment of drusen to prevent progression to advanced age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Parodi, Maurizio B ^a   Virgili, Gianni ^b   Evans, Jennifer R ^c  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION COEFFICIENT; DISEASE COURSE; DRUSEN; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LASER COAGULATION; LOW LEVEL LASER THERAPY; OUTCOME ASSESSMENT; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; READING; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 70049083998     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006537.pub2     Document Type: Review

References (76)

1. Alexander J, Elsner KS, Javornik NB, Whittock ER, Brightwell-Arnold M, Duncan JL, et al.CAPT Study Group. Characteristics of exudation in patients with bilateral large drusen. Investigative Ophthalmology & Visual Science 2004;45:ARVO E-abstract 2989.
2. * Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology 2006;113(11):1974-1986
3. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clinical Trials 2004;1(1):91-107.
4. Figueroa M, Schocket LS, DuPont J, Metelitsina TI, Grunwald JE. Effect of laser treatment for dry age related macular degeneration on foveolar choroidal haemodynamics. British Journal of Ophthalmology 2004;88(6):792-795 (Pubitemid 38725590)
5. Figueroa M, Schocket LS, DuPont J, Metelitsina TI, Grunwald JE. Long-term effect of laser treatment for dry age-related macular degeneration on choroidal hemodynamics. American Journal of Ophthalmology 2006;141(5):863-867
6. Grunwald JE, Figueroa M, Metelitsina TI, Schocket LS, DuPont JC. Effect of CAPT laser treatment on choroidal hemodynamics in agerelated macular degeneration (AMD). Investigative Ophthalmology & Visual Science 2004;45:ARVO E-abstract 3133. (Pubitemid 38725590)
7. Maguire M, Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 2004;111(7):1307-1316
8. Sbarbaro JA, Maguire MG. CAPT Study Group. Annual changes in refractive error over 3 years among eyes with early AMD. Investigative Ophthalmology & Visual Science 2004;45:ARVO E-abstract 3055.
9. Stoltz RA, Ying GS, Alexander J. CAPT Study Group. Fundus features of untreated eyes with visual acuity loss in CAPT. Investigative Ophthalmology & Visual Science 2004;45:ARVO E-abstract 1389.
10. Ying GS, Liu C, Maguire MG. CAPT Research Group. Night-vision symptoms as a risk factor for vision loss and choroidal neovascularization in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT). Investigative Ophthalmology & Visual Science 2005;46:ARVO E-abstract 204.
11. Anonymous. Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial. The Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1998;105(8):1364-1372
12. Anonymous. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1998;105(1):11-23.
13. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology 2003;110(5):971-978
14. Fine SL, Maguire MG, Javornik NB, Ho AC. CNVPT Research Group. The choroidal neovascularization prevention trial (CNVPT): 4-year results. Investigative Ophthalmology & Visual Science 2001;42:ARVO Abstract 676.
15. Ho AC, Maguire MG, Yoken J, Lee MS, Shin DS, Javornik NB, et al.Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1999;106(7):1367-1373
16. Ho AC, Yoken J, Lee MS, Shin DS, Javornik NB, Maguire MG, et al.Laser-induced drusen reduction improves visual function at one year. American Academy of Ophthalmology 1998:127.
17. Kaiser RS, Berger JW, Maguire MG, Ho AC, Javornik NB. Choroidal Neovascularization Prevention Trial Study Group. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study. Archives of Ophthalmology 2001;119(6):826-832
18. Prenner JL, Rosenblatt BJ, Tolentino MJ, Ying GS, Javornik NB, Maguire MG, et al. CNVPT Research Group. Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina (Philadelphia, Pa.) 2003;23(3):307-314
19. Regillo CD. Laser treatment in felloweyes with large drusen: updated findings from a pilot randomized clinical trial. Evidence-Based Eye Care 2003;4(4):204-205 (Pubitemid 38867690)
20. Rosenbaltt BJ, Prenner JL, Tolentino M, Ying G, Javornik NB, Maguire MG, et al. CNVPT Research Group. Predictors of visual acuity loss in the fellow eye study of the Choroidal Neovascularization Prevention Trial (CNVPT). Investigative Ophthalmology & Visual Science 2001;42:ARVO Abstract 675.
21. Kertes PJ. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study - Commentary. Evidence-Based Ophthalmology 2006;7(3):135-137 (Pubitemid 44621346)
22. Owens SL, Bunce C, Brannon AJ, Wormald R, Bird AC. Drusen Laser Study Group. Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis. Eye (London, England) 2003;17(5):623-627 (Pubitemid 36927107)
23. Owens SL, Bunce C, Brannon AJ, Xing W, Chisholm IH, Gross M, et al. Drusen Laser Study Group. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. American Journal of Ophthalmology 2006;141(2):276-281 (Pubitemid 43188026)
24. Owens SL, Guymer RH, Gross-Jendroska M, Bird AC. Fluorescein angiographic abnormalities after prophylactic macular photocoagulation for high-risk age-related maculopathy. American Journal of Ophthalmology 1999;127(6):681-687 (Pubitemid 29266744)
25. Figueroa MS, Regueras A, Bertrand J. Laser photocoagulation to treat macular soft drusen in age-related macular degeneration. Retina (Philadelphia, Pa.) 1994;14(5):391-396
26. Figueroa MS, Regueras A, Bertrand J, Aparicio MJ, Manrique MG. Laser photocoagulation for macular soft drusen. Updated results. Retina (Philadelphia, Pa.) 1997;17(5):378-384 (Pubitemid 28076366)
27. Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. British Journal of Ophthalmology 1998;82(10):1169-1174 (Pubitemid 28474874)
28. Frennesson CI. Prophylactic laser treatment in early age-related maculopathy: an 8-year follow-up in a randomized pilot study shows a reduced incidence of exudative complications. Acta Ophthalmologica Scandinavica 2003;81(5):449-454
29. Frennesson IC, Nilsson SE. Effects of argon (green) laser treatment of soft drusen in early age-related maculopathy: a 6 month prospective study. British Journal of Ophthalmology 1995;79(10):905-909
30. Frennesson IC, Nilsson SE. Laser photocoagulation of soft drusen in early age-related maculopathy (ARM). The one-year results of a prospective, randomised trial. European Journal of Ophthalmology 1996;6(3):307-314 (Pubitemid 26346060)
31. Bressler SB, Vitale S, Hawkins BS, Alexander J, Orr PR, Schachat AP, et al.Laser to Drusen Trial: an assessment of short term safety within randomized, prospective, controlled clinical trial. Investigative Ophthalmology & Visual Science. 1995:ARVO abstract 1028.
32. Little HL, Showman J. A pilot randomized, controlled study on the effect of laser photocoagulation of confluent soft macular drusen. American Academy of Ophthalmology 1995:120. (Pubitemid 27171983)
33. Little HL, Showman JM, Brown BW. A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology 1997;104(4):623-631
34. Olk RJ, Friberg TR, Stickney KL, Akduman L, Wong KL, Chen MC, et al.Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology 1999;106(11):2082-2090 (Pubitemid 30194228)
35. Friberg TR, Musch DC, Lim JI, Morse L, Freeman W, Sinclair S. PTAMD Study Group. Prophylactic treatment of age-related macular degeneration Report Number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology 2006;113(4):612-622
36. Rodanant N, Friberg TR, Cheng L, Aurora A, Bartsch D, Toyoguchi M, et al.Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration. American Journal of Ophthalmology 2002;134(4):577-585 (Pubitemid 35304648)
37. Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. British Journal of Ophthalmology 1999;83(3):358-368
38. Sigelman J. Foveal drusen resorption one year after perifoveal laser photocoagulation. Ophthalmology 1991;98(9):1379-1383
39. Sivagnanavel V, Chong V. Diffuse laser for drusen reduction in high risk age-related maculopathy. Investigative Ophthalmology & Visual Science 2004;45:ARVO E-abstract 3097.
40. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Survey of Ophthalmology 1999;44(1):1-29. (Pubitemid 29378350)
41. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Archives of Ophthalmology 2001;119(10):1417-1436
42. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina 1994;14(2):130-142
43. Bressler NM, Munoz B, Maguire MG, Vitale SE, Schein OD, Taylor HR, et al.Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Archives of Ophthalmology 1995;113(3):301-308
44. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, et al.The burden of age-related macular degeneration: a value-based analysis. Current Opinion in Ophthalmology 2006;17(3):257-266 (Pubitemid 44309749)
45. Chakravarthy U, Stevenson M. Self-reported visual functioning and quality of life in age-related macular degeneration. Current Opinion in Ophthalmology 2005;16(3):179-183 (Pubitemid 40694978)
46. Chong EW, Wong TY, Kreis AJ, Simpson JA, Guymer RH. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 2007;335(7623):755.
47. Cleasby GW, Nakanishi AS, Norris JL. Prophylactic photocoagulation of the fellow eye in exudative senile maculopathy. A preliminary report. Modern Problems in Ophthalmology 1979;20:141-147
48. Duvall J, Tso MO. Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study. Archives of Ophthalmology 1985;103(5):694-703. (Pubitemid 15052409)
49. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004;122:564-572
50. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-149 (Pubitemid 34284916)
51. Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2006, Issue 2. [Art. No.: CD000254. DOI: 10.1002/14651858.CD000254. pub2]
52. Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. British Journal of Ophthalmology 1998;82(10):1169-1174 (Pubitemid 28474874)
53. Gass JD. Drusen and disciform macular detachment and degeneration. Archives of Ophthalmology 1973;90(3):206-217
54. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-136
55. Gross-Jendroska M, Owens SL, Flaxel CJ, Guymer RH, Bird AC. Prophylactic laser treatment to fellow eyes of unilateral retinal pigment epithelial tears. American Journal of Ophthalmology 1998;126(1):77-81. (Pubitemid 28341221)
56. Guidry C, Medeiros NE, Curcio CA. Phenotypic variation of retinal pigment epithelium in age-related macular degeneration. Investigative Ophthalmology & Visual Science 2002;43(1):267-273 (Pubitemid 34032469)
57. Guymer RH, Hageman GS, Bird AC. Influence of laser photocoagulation on choroidal capillary cytoarchitecture. British Journal of Ophthalmology 2001;85(1):40-46 (Pubitemid 32060193)
58. Hassell JB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. British Journal of Ophthalmology 2006;90(5):593-596
59. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
60. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
61. Holz FG, Wolfensberger TJ, Piguet B, Gross-Jendroska M, Wells JA, Minassian DC, et al.Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994;101(9):1522-1528 (Pubitemid 24347050)
62. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. American Journal of Ophthalmology 2004;137(3):486-495
63. Maguire M, Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 2004;111(7):1307-1316
64. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. American Journal of Ophthalmology 1999;128(1):45-53. (Pubitemid 29315762)
65. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Archives of Ophthalmology 1997;115(6):741-747
66. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?. British Journal of Ophthalmology 2003;87:312-317 (Pubitemid 36307906)
67. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane. A histochemical and morphologic study. Ophthalmology 1990;97(2):171-178 (Pubitemid 20051380)
68. Pauleikhoff D, Chen JC, Chisholm IH, Bird AC. Choroidal perfusion abnormality with age-related Bruch's membrane change. American Journal of Ophthalmology 1990;109(2):211-217 (Pubitemid 20048421)
69. Phipps JA, Guymer RH, Vingrys AJ. Loss of cone function in agerelated maculopathy. Investigative Ophthalmology & Visual Science 2003;44(5):2277-2283
70. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
71. Sarraf D, Gin T, Yu F, Brannon A, Owens SL, Bird AC. Long-term drusen study. Retina 1999;19(6):513-519
72. Smith W, Assink J, Kein R, Mitchell P, Klaver CCW, Klein BEK, et al.Risk factors for age-related macular degeneration. Pooled findings from three continents. Ophthalmology 2001;108:607-704. (Pubitemid 32238465)
73. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Archives of Ophthalmology 1996;114(10):1193-1196 (Pubitemid 26338849)
74. Wetzig PC. Photocoagulation of drusen-related macular degeneration: a long-term outcome. Transactions of the American Ophthalmological Society 1994;92:299-303.
75. White IR, Higgins JPT, Wood AM. Allowing for uncertainty due to missing data in meta-analyses. Part 1: two-stage methods. Statistics in Medicine 2008;27:711-727 (Pubitemid 351278815)
76. Young RW. Pathophysiology of age-related macular degeneration. Survey of Ophthalmology 1987;31(5):291-306.